Mirtazapine Tablets

Mirtazapine has a tetracyclic structure and belongs to the piperazine-diazepine class of compounds. The mechanism of action of this product in the treatment of severe depression is still unclear. Preclinical trials have shown that this product can enhance the activity of central norepinephrine and 5-hydroxytryptamine, which may be related to the fact that this product is a central presynaptic inhibitory α2 adrenergic receptor antagonist. Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors, but has no obvious affinity for 5-HT1A and 5-HT1B receptors. At the same time, mirtazapine is a potent antagonist of H1 receptors, which may be related to its obvious sedative effect; mirtazapine has a moderate antagonistic effect on α1 adrenergic receptors, which may be related to the occasional orthostatic hypotension reported during its action; mirtazapine has a moderate antagonistic effect on M receptors, which may be related to the relatively low incidence of anticholinergic side effects.

Mirtazapine.

This product is a film-coated tablet, which appears white or off-white after removing the film coating.

depression.

Oral administration, can be swallowed with water, do not chew. The starting dose for adult treatment is once a day, 15 mg (1/2 tablet) each time, and then gradually increase the dose to achieve the best therapeutic effect. The effective oral dose is usually 15-45 mg per day (1/2 tablet-1.5 tablets). Patients with liver and kidney damage have reduced clearance of mirtazapine, so such patients should be careful when taking the drug. The half-life of mirtazapine is 20-40 hours, so the medication can be taken once a day, and the effect is better when taken before going to bed. It can also be divided into two doses, once in the morning and once in the evening. Patients should continue to take the medication, and it is best to stop the medication 4-6 months after the symptoms completely disappear. The appropriate dose will have a significant effect within 2-4 weeks. If the effect is not obvious, the dose can be increased to the maximum dose. If there is still no significant effect within 2-4 weeks after the increase, the medication should be stopped immediately.

1. Patients with depression often show a series of disease-related phenomena, so it is sometimes difficult to determine whether a phenomenon is a manifestation of the disease itself or an adverse reaction after taking mirtazapine. Common adverse reactions to taking mirtazapine include: 1) Increased appetite and weight gain. 2) Fatigue and sedation, which usually occur within one week after taking the medicine (Note: a reduction in dosage at this time will not alleviate this adverse reaction, but will affect the treatment effect of depression). 2. In rare cases, the following symptoms may occur: 1) (Postural) hypotension 2) Mania 3) Seizures, tremors and muscle spasms 4) Edema and corresponding weight gain 5) Acute bone marrow suppression (granulocytopenia, aplastic anemia, thrombocytopenia, and decreases in various types of cells) (see Precautions for Use) 6) Increased serum transaminases 7) Drug rash

Do not use if you are allergic to mirtazapine.

Precautions for children: Since the effectiveness and safety of this drug for children have not been confirmed, it is not recommended for children to use this drug. Precautions for pregnancy and lactation: 1. There are not enough clinical trial results to evaluate the effect of Remeron on pregnancy. In animal experiments, this drug has no teratogenic side effects such as toxicity to the embryo. 2. Although only a very small amount of drug ingredients can be secreted from the milk of animals, due to the lack of clinical trial data, it is not recommended for lactating patients to take this drug. Precautions for the elderly: The dosage is the same as that for adults, and the dosage should be gradually increased under the close observation of a doctor in order to achieve a satisfactory therapeutic effect.

1. Mirtazapine may aggravate the depressant effect of alcohol on the central nervous system, so drinking is prohibited during treatment. 2. Avoid using it simultaneously with monoamine oxidase or using it less than 14 days apart. 3. Mirtazapine may aggravate the sedative effect of benzodiazepines, so caution should be exercised when using these drugs simultaneously with mirtazapine.

Keep in a dark, sealed, and cool place (not exceeding 20°C).

30 mg

Tentatively set at 36 months.

HUA-YU (WUXI) Pharmaceutical Co., Ltd.

• Founded in:

  1993-01-19

• Address:

  2nd Floor, Building 7, Phase II, Biomedical R&D Service Outsourcing Zone, No. 138 Meiliang Road, Mashan, Wuxi

• Tax NO.:

  91320200607912858J

• Registered Funds:

  $20 million

• Website:

  Log in to view

• Email:

  Log in to view